Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0HPXEI
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
tORL-5-700
|
|||||
| Synonyms |
TORL-5-700
Click to Show/Hide
|
|||||
| Organization |
TORL Biotherapeutics (Originator)
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Antibody Name |
undisclosed
|
Antigen Name |
Undisclosed
|
|||
| Payload Name |
Undisclosed
|
|||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Undisclosed
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Diffuse large b-cell lymphoma |
1 Trials
|
||||||||
| Follicular lymphoma |
1 Trials
|
||||||||
| Mantle cell lymphoma |
1 Trials
|
||||||||
| Unspecific non-hodgkin lymphoma |
1 Trials
|